Transfer of a chromosomal locus responsible for mucoid colony morphology in Pseudomonas aeruginosa isolated from cystic fibrosis patients to P. aeruginosa PA0
Introduction
The lungs of patients suffering from cystic fibrosis (CF) invariably become infected with Pseudomonas aeruginosa (May et al., 1972) . Antibiotic treatment may not eradicate the organism but is usually clinically beneficial (Hodson et al., 198 1) . Inevitably, however, a P. aeruginosa variant known as "mucoid" (from the appearance of the colonies upon culture) appears in the lung (Doggett et al., 1966) , and subsequently the prognosis is poor (Wood et al., 1976; Henry et al., 1982) .
The mucoid colonial characteristics of such P. aeruginosa variants are due to the production of alginic acid, a 1 ,4-linked7 selectively acetylated, copolymer of /?-D-mannuronic acid and its C-5 epimer a-L-glucuronic acid (Fyfe and Govan, 1983) . The enzymology of alginic acid synthesis has not yet been elucidated. Pugashetti et al. (1 983) suggested that it is synthesised via the Entner-Doudoroff pathway-G-P-D mannose dehydrogenase, which converts G-P-D mannose to G-P-D mannuronate, being the major enzyme-whereas Banerjee et al. (1983) postulated that synthesis occurs via glyceraldeh yde-3-phosphate.
Two different approaches have been used in attempts to elucidate the genetics of mucoid variation. Established systems of gene transfer and recombination are a basic prerequisite of any Received 7 May 1985; accepted 31 Jul. 1985. colony morphology.
genetic study, and P. aeruginosa strain P A 0 is the most extensively characterised pseudomonad in this respect (Holloway et al., 1979; Holloway and Matsumoto, 1984) . In the first approach Govan and Fyfe (1978) and Fyfe and Govan (1983) have studied the genetics of mucoid mutants derived from P. aeruginosa PAO. However, there is no assurance that such mutants bear any relationship to mucoid strains of P. aeruginosa isolated from C F patients.
The second approach was to take a clinical mucoid strain of P. aeruginosa, introduce into it auxotrophic and non-mucoid mutations, and by use of chromosome-mobilising plasmids previously described for PAO, attempt to map the loci involved in mucoid production in that strain (Ohman and Chakrabarty, 198 1) . A difficulty of this approach is that there is no easy way of relating auxotrophic and other loci mapped in this manner to the established P. aeruginosa P A 0 genetic map.
We have used a third approach which minimises objections to the above methods. We have performed experiments to demonstrate the conjugal transfer of chromosomal loci (muc) causing the mucoid phenotype to P. aeruginosa PAO, and to relate these loci to markers on the P. aeruginosa P A 0 genetic map. In these crosses we have used the enhanced chromosome mobilising (ECM) plasmid pM060 (Riess et al., 1980) , which is similar to R68.45 (Haas and Holloway, 1976) but showed much greater stability of chromosome-mobilising ability.
Materials and methods

Bacterial strains and plasmids
These are listed in table I.
Media and cultural conditions
Medium P (Leisinger et al., 1972) Stanisich and Holloway, 1972) and were stored over chloroform and used at a final concentration of 1 mM except for isoleucine which was used P. aeruginosa P A 0 strains are derived from PA01 (ATCC 15692), Ps strains are clinical isolates of P. aeruginosa and PAM strains are recombinants derived from conjugal crosses between mucoid clinical isolates and P A 0 which exhibit the mucoid phenotype. Genotype symbols are the same as those used by Bachmann (1983) for Escherichia coli except that str signifies streptomycin resistance, nal resistance to nalidixic acid, pru proline utilisation and muc involvement in mucoid colony phenotype. Phenotype symbols: Cb, carbenicillin resistance, Km/Nm, kanamycin/ neomycin resistance; Tc, tetracycline resistance; Sm, streptomycin resistance; Cm, chloramphenicol resistance; Tra, conjugative ability; Cma, chromosome mobilizing ability; Muc, mucoid colony mo.rphology (Muc+, mucoid; Muc-, nonmucoid). *The map positions of markers relevant to this study are shown in the figure.
at 0.5 mM. When appropriate, media were supplemented with (/L) carbenicillin (Pyopen; Beecham, Australia) 500 mg, streptomycin (Sigma Chemical Co.) 500 mg, or tetracycline (oxytetracycline tetrachloride; Sigma) 200 mg. Strains with ability to use proline as sole carbon source (Pru+) were selected on Medium P supplemented with proline 0.1% w/v. All cultures were incubated at 3 7 T , except P A 0 strains to be used as recipients in crosses with clinical strains which were grown in nutrient yeast broth at 43°C; this renders P. aeruginosa P A 0
phenotypically restrictionless for about 60 generations of growth at 37°C (Holloway, 1965) .
Bacteriological techniques
Plate matings (Stanisich and Holloway, 1972 ) and carbenicillin semi-selection of auxotrophs after mutagenesis with ethyl methane sulphonate (Sigma) (Watson and Holloway, 1976) were performed as described. Pyocin typing of clinical isolates was performed by the method of Gillies and Govan (1966) .
Results
During a 2-year period we have received more than 150 mucoid clinical isolates of P . aeruginosa from CF patients at the Royal Children's Hospital, Melbourne. These isolates showed considerable variation in growth rate and in the amount of alginate produced on peptone fructose agar; interestingly, in view of the often reported instability of the mucoid phenotype upon subculture, most of our strains were quite stable (data not shown). We chose for further study five stable mucoid isolates (listed in table I) that showed a good growth rate and which had been isolated from unrelated patients. Of these five isolates, only Ps3738 could be distinguished from the rest by pyocin typing (Gillies and Govan, 1966) ; it was of pyocin type 29, the other four being of type 5. Of the four type-5 isolates, Ps3694 and Ps37 10 were gentamicin resistant, whereas Ps3712 and Ps3739 were gentamicin sensitive (information provided by the Royal Children's Hospital). Thus it is not possible for us to state unequivocally that our five isolates represent more than three genetically distinct strains.
Transfer of muc loci to P . aeruginosa P A 0
Initial attempts to transfer the gene or genes responsible for the mucoid phenotype to P . aeruginosa P A 0 involved the use of the ECM plasmid pM0887 which does not carry genes for tetracycline resistance (TcR). This plasmid was transferred to a mucoid clinical isolate by selection for carbenicillin resistance. This strain was then used as a donor with various multi-marked P A 0 recipients carrying the IncQ plasmid pKT2 12, which confers TcR, with selection for both TcR and prototropy of individual auxotrophic markers. The rationale behind this approach is that we have never observed mutation to high-level tetracycline resistance in P . aeruginosa. A similar procedure was used successfully to allow large numbers of clinical isolates of P . aeruginosa to be readily screened for chromosome-mobilising plasmids (Dean et al., 1979) . However, for the analysis of mucoid strains this approach proved to be unsatisfactory for two reasons. First, although pM0887 is stable in P . aeruginosa P A 0 it was highly unstable in all five clinical isolates, losing chromosome-mobilising ability at a high frequency. Second, a more serious problem was "back transfer" of pKT2 12 to the clinical isolate; pKT2 12 was mobilised by pM0887 which had transferred to the P A 0 recipient at high frequency without direct selection. This transfer of pKT212 resulted in the mucoid donors acquiring TcR and growing on the mating plates.
These problems were overcome by introducing ethyl methane sulphonate-induced auxotrophic mutations into each of the five clinical isolates to provide a contraselective marker, and by transferring pM060 to each clinical strain by selection for carbenicillin resistance. This naturally occurring ECM plasmid proved to be quite stable in all five clinical isolates tested. Auxotrophic derivatives of the clinical isolates, carrying pM060, were plate mated with various multi-marked P . aeruginosa P A 0 recipients, selection was applied for protrophy of single markers, and the mating plates were screened for the appearance of mucoid recombinants. For each clinical isolate donor, prototrophic recombinants were formed at a frequency of about 10-6/donor cell, which is about 10-100-fold less than would be expected in PAOxPAO (pM060) plate matings (data not shown). When selection was made for prototrophy of markers in the pur-70-proB region of the chromosome (see figure) , 10-1 5% of the recombinant colonies were mucoid when Ps3694-2, Ps37 10-1 7 or Ps37 12-1 5 carrying pM060 were the donors, but with Ps3738-1 and Ps3739-1 carrying pM060 as donors, only about 1% of the recombinant colonies were mucoid (data not shown). With all five clinical isolates, however, selection for other markers failed to yield any mucoid recombinants (data not shown). This result suggested that the muc gene or genes being transferred had a chromosomal location; if a plasmid was being mobilised from the clinical isolates apparent linkage to all chromosomal markers used to select recombinants would be expected. It was assumed that the mucoid P A 0 derivatives now carried a small region (probably 5' -1 0', and including the muc gene or genes) of chromosome from the clinical isolates in place of the homologous P A 0 chromosomal region.
Mapping of the muc locus
To determine the location of the muc gene or genes more accurately, one recombinant mucoid clone from each cross was chosen for further study. We have designated these five clones as PAM strains, and the particular derivation of each is shown in table I. Selection for carbenicillin resistance was used to transfer pM060 into each of the PAM strains which were then used as donors in plate matings with strain PAO1052, or strain PA06020 in the case of PAM207 (pM060) because PAM207 required threonine. Subsequent selection was made for one or more prototrophic marker. The co-inheritance values obtained from the cross PAM404 (pM060) x PA01052 are shown in table 11. As expected, muc is linked to all three markers in the pur-70-proB region but unlinked to thr-48 (figure). When cys-59+ was the selected marker the observation that none of the Muc-recombinants were Pur+, whereas 88% of them were Pro+ suggested that muc is to the left of cys-59 in the figure. This was confirmed when cys-59+ and pur-70+ were selected simultaneously because all of the Cys+ Pur+ recombinants were Muc+, which indicates that muc is located between pur-70 and cys-59. Although it would be possible to obtain such a result if muc were located to the left of pur-70 providing that they were very lightly linked, it was found that the co-inheritance of pur-70 and muc-3739 was only 37%.
Matings between the other four PAM strains carrying pM060 and PA01052, or PA06020 in the case of PAM207 (pM060), gave similar results. Thus all five PAM strains behaved as though they differed from P A 0 at a single muc locus, located between pur-70 and cys-59. However, for a given PAM strain it is not possible to say that only one muc locus is involved in producing the mucoid phenotype. Although the Muc+ recombinant colonies from a given PAM (pM060)xPAO cross were morphologically indistinguishable, and segregation of muc loci in these crosses might have been expected to yield mucoid colonies of distinguishable phenotype, it is possible that segregation of muc loci was occurring undetected. However, if more than one locus is involved, such loci must be tightly linked.
It is also impossible to say that the five PAM strains differ from strain P A 0 at the same locus. Although they were indistinguishable from each other in colony morphology, further genetic analysis is required to answer this point.
The P . aeruginosa P A 0 genetic map carries a proline utilisation marker (pru-365) between pru-70 and cys-59 (figure). To determine the relative positions of muc-3739 and pru-365 on the genetic map, PAM739 (pM060) was plate mated with PA06021. When proB65+ was the selected marker, 99% of Muc+ recombinants were Pru+. Because Muc-Pru+ recombinants were not recovered, the most probable order of the markers is muc-pru-pro. For reasons that we are unable to explain, Pru+ recombinants were not recovered by direct selection, even though such recombinants can be recovered at the expected frequencies in PAOxPAO crosses.
Discussion
The transfer of a locus causing the production of alginate in P . aeruginosa isolates from CF patients to P . aeruginosa PAO, and its subsequent expression in that strain, opens the way to a genetic analysis of the nature of this locus, and will allow a comparison with those P . aeruginosa P A 0 loci that have been identified by Fyfe and Govan (1983) as being responsible for alginate production. These workers have mapped two such loci, closely linked to but on either side of cys-59, and phenotypically distinguishable on the basis of colony morphology. Group-1 mutations, represented by muc-23 which maps to the right of cys-59, yield mucoid colonies on minimal agar, whereas group-2 mutations, represented by muc-22 which maps to the left of cys-59, gives rise to non-mucoid colonies on minimal agar. All five PAM strains generated in this study form mucoid colonies on minimal agar and hence carry group-1 mutations but our linkage data clearly indicate a position for muc to the left of cys-59. Furthermore, although muc-22 maps to the right of pru (Fyfe and Govan, 1983) , our data suggest that muc-3739 (carried by PAM404) maps to the left of pru. Clearly, more than one locus is involved, and more precise mapping of further mutations either generated in P. aeruginosa P A 0 or transferred to P A 0 from mucoid clinical isolates is required before any conclusions can be drawn.
It is more difficult to correlate our findings with those of Ohman and Chakrabarty (1981) who investigated three closely linked loci, denoted alg, in a mucoid clinical isolate that could mutate to suppress the mucoid phenotype. Moreover, the location of these alg loci was determined by Ohman and Chakrabarty in relation to a range of auxotrophic markers generated in their clinical isolate. Thus is is not possible to relate the location of any of these loci to the P . aeruginosa P A 0 chromosome which serves as a reference point for genetic studies in this organism. In a later study, and using another mucoid clinical isolate, Darzins and Chakrabarty (1984) mapped a mutation that suppressed the mucoid phenotype to 19' on the P A 0 chromosome map. They were able to do this because a clone from a cosmid gene bank, identified by its ability to complement the alg-suppressor mutation (i.e., restore the mucoid phenotype), also carried the argH+ wild-type gene which is located at 19' (Holloway and Matsumoto, 1984) . These workers also identified three other alg-loci on the basis of complementation by different clones from their cosmid bank, but were not able to determine the chromosomal locations of these loci. Isolation and mapping of the mucoid suppressor mutations in the PAM strains described in this paper will determine the map positions of suppressor loci.
A reported feature of mucoid strains is their instability during culture (Zierdt and Schmidt, 1964; Govan, 1975; Fyfe and Govan, 1983) . Govan (1 975) reported that the use of desoxycholate citrate agar allows maintenance of the mucoid colony morphology. We noted early in this study that our strains appeared quite stable for the mucoid phenotype. Boyce and Miller (1 98 l ) reported that supplementation of the growth medium with 0 . 0 3~ FeC13 led to rapid overgrowth of the culture by nonmucoid revertants, and preliminary studies with our PAM strains support this (data not shown). This leads to interesting speculations as to the role of Fe+ + + in the emergence and maintenance of the mucoid phenotype in the lungs of C F patients. 
